Investor Relations
May 18, 2018
OPKO Plans to Address Draft Local Coverage Determination Published by Novitas Solutions for 4Kscore Test MORE >>
May 08, 2018
OPKO Health Reports First Quarter 2018 Financial Results MORE >>
May 02, 2018
OPKO Health to Announce First Quarter 2018 Financial Results on May 8, 2018 MORE >>
May 01, 2018
OPKO Health Appoints Geoff Monk General Manager at BioReference Laboratories MORE >>

Press Releases

All Releases
OPKO Health to Be Present at the Barrington Research Fall Investment Conference
Aug 25, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that senior management will attend the Barrington Research Fall Investment Conference on Tuesday, September 1, 2015 in Chicago and will be available for one on one meetings. About OPKO Health, Inc.
OPKO Completes Acquisition of Bio-Reference Laboratories
Aug 20, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK) and Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) today announced the completion of the acquisition of Bio-Reference by OPKO. Shareholders of Bio-Reference will receive 2.75 shares of OPKO common stock for each share of Bio-Reference common
OPKO Lab Signs Contracts with Leading Preferred Provider Networks for Laboratory Testing Services Including the 4Kscore® Test
Aug 19, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that it has entered into agreements with Stratose , Three Rivers Provider Network and Fortified Provider Network for testing services from OPKO Lab , including the 4Kscore®Test, the only blood test that accurately identifies an
OPKO Announces Second Quarter Operating and Financial Results
Aug 05, 2015
Announced the Acquisition of Bio-Reference Laboratories; Closing Anticipated by the End of August Acquired EirGen Pharma , A Growing, Profitable Specialty Pharmaceutical Developer and Manufacturer Rayaldee TM New Drug Application (NDA) Submission Accepted by FDA ; Expected PDUFA date of March 29,
Two Reports on hGH-CTP Pediatric Phase 2 Clinical Data Accepted for Oral Presentation at the 54th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE conference)
Aug 05, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK), announced that additional data from OPKO's hGH-CTP pediatric Phase 2 clinical trials summarized in two abstracts entitled, " 12 month Safety and efficacy of a weekly long-acting growth hormone (GH, MOD-4023) compared to daily recombinant human
OPKO To Announce Second Quarter Operating and Financial Results on August 5, 2015
Jul 30, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK ) will announce second quarter 2015 operating and financial results on Wednesday August 5th , after the close of the U.S. financial markets. OPKO's senior management will host a conference call and live audio webcast to provide a business
FDA Accepts OPKO's New Drug Application for Rayaldee™
Jul 28, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review OPKO's New Drug Application (NDA) for calcifediol modified-release capsules (proposed trade name, Rayaldee™).
OPKO Announces Completion of Enrollment in Phase 3 Trial of hGH-CTP in Growth Hormone Deficient Adults
Jul 10, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health , Inc. (NYSE:OPK) has completed enrollment in the single pivotal Phase 3 trial of its long acting human growth hormone (hGH-CTP) in growth hormone deficient (GHD) adults. The trial is designed to evaluate the safety and efficacy of hGH-CTP with a primary
OPKO Investee SciVac Announces the Completion of Transaction with Levon Resources
Jul 10, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) is pleased to announce that SciVac Ltd. (" SciVac "), an Israeli entity in which OPKO has a forty-five percent ownership interest, completed its previously announced plan of arrangement under Section 288 of the Business Corporations Act (
OPKO and Bio-Reference Laboratories Announce Early Termination of the Waiting Period for Planned Acquisition
Jul 02, 2015
  MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (OPK) and Bio-Reference Laboratories, Inc. (BRLI), today announced that early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") has been granted, effective July 1, 2015 , for OPKO's
Conversion Right Extended on OPKO 3.0% Convertible Senior Notes
Jul 01, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK) today announced that the Company's 3.0% Convertible Senior Notes due 2033 (the "Notes") continue to be convertible by holders of such Notes through September 30, 2015 . The Company has elected to satisfy its conversion obligation under the
OPKO 4Kscore® Recommended in National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection
Jun 26, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced the decision of the National Comprehensive Cancer Network (NCCN) to include 4Kscore® as a recommended test in the 2015 NCCN Guidelines for Prostate Cancer Early Detection. The panel concluded that the 4Kscore, as a blood test
OPKO to Present New Data at International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress on Its Long-Acting Clotting Factor VIIa
Jun 09, 2015
New Preclinical Data further demonstrate the safety and efficacy of MOD-5014 (FVIIa -CTP) for both Intravenous and Subcutaneous Administration MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK), today announced that the company will present new data on its long-acting clotting Factor VIIa-CTP
OPKO and Bio-Reference Laboratories To Hold Joint Conference Call to Discuss Merger
Jun 08, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK ) and Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) will host a joint conference call and webcast at 8:30 a.m. ET on Thursday , June 11, 2015 , to discuss the previously announced entry into a merger agreement for OPKO to acquire
OPKO Health to Acquire Bio-Reference Laboratories
Jun 04, 2015
Complementary in-depth expertise in diagnostics business with state of the art experience in use of genomic data for personalized therapy Acquisition provides national sales force to accelerate adoption of OPKO's 4Kscore TM test for aggressive prostate cancer MIAMI --(BUSINESS WIRE)-- OPKO HEALTH,
OPKO Announces Submission of Rayaldee™ New Drug Application to U.S. Food and Drug Administration
May 29, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK), today announced that it has submitted a New Drug Application (NDA) for oral Rayaldee to the U.S. Food and Drug Administration (FDA). The NDA requests marketing approval for Rayaldee for the prevention and treatment of secondary
OPKO Health to Present at the Jefferies 2015 Healthcare Conference
May 27, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the Jefferies 2015 Healthcare Conference on Wednesday, June 3, 2015 at 4:00 PM EDT in New York City . The presentation will be webcast on the OPKO Investor Relations page of the corporate
OPKO Announces 4Kscore® Abstracts at the 2015 American Urological Association (AUA) Annual Meeting
May 18, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced six important new clinical trial results pertaining to the 4Kscore® test presented at the 2015 American Urological Association (AUA) annual meeting, May 15 to May 19, 2015 , in New Orleans .
OPKO Announces Publication of Study Using Kallikrein Biomarkers of the 4Kscore® Test in a Large Community-Based Referral Cohort
May 15, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced the online publication of a study entitled " A Four-kallikrein Panel Predicts High -grade Cancer on Biopsy: Independent Validation in a Community Cohort " in the journal European Urology .
OPKO Announces First Quarter Operating and Financial Results
May 11, 2015
Pfizer Collaboration Agreement for Long Acting Human Growth Hormone Closed in January 2015 ; OPKO Received $295 million of $570 Million Total Potential Pre-Commercialization Payments Acquired EirGen Pharma, A Growing, Profitable Specialty Pharmaceutical Developer and Manufacturer Rayaldee TM New
Displaying 121 - 140 of 353